Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 63

1.

[Changes in the characteristics of paradoxical sleep are an early feature of Parkison's disease].

Pastukhov IuF.

Zh Vyssh Nerv Deiat Im I P Pavlova. 2013 Jan-Feb;63(1):75-85. Review. Russian.

PMID:
23697224
2.
3.

Does smoking reduce the risk of Parkinson's disease through stimulation of the ubiquitin-proteasome system?

Chapman MA.

Med Hypotheses. 2009 Dec;73(6):887-91. doi: 10.1016/j.mehy.2009.03.053. Epub 2009 Jun 18.

PMID:
19540050
4.

[ROLE OF THE INDUCIBLE Hsp70 PROTEIN IN MODULATION OF NEURODEGENERATIVE PATHOLOGY OF NIGROSTRIATAL SYSTEM TYPICAL FOR THE PARKINSON'S DISEASE].

Ekimova IV, Plaksina DV, Guzhova IV, Meshalkina DA.

Zh Evol Biokhim Fiziol. 2016 Jan-Feb;52(1):73-5. Russian. No abstract available.

PMID:
27220243
5.
6.

[Content of chaperon Hsp70 in dopaminergic neurons of the black substance increases in proteasome dysfunstion].

Pastukhov IuF, Ekimova IV, Guzhova IV, Romanova IV, Artiukhina ZE.

Ross Fiziol Zh Im I M Sechenova. 2011 Jul;97(7):649-60. Russian.

PMID:
21961290
7.

Colchicine protects dopaminergic neurons in a rat model of Parkinson's disease.

Salama M, Ellaithy A, Helmy B, El-Gamal M, Tantawy D, Mohamed M, Sheashaa H, Sobh M, Arias-Carrión O.

CNS Neurol Disord Drug Targets. 2012 Nov 1;11(7):836-43.

PMID:
23198691
8.

The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.

Ross CA, Pickart CM.

Trends Cell Biol. 2004 Dec;14(12):703-11. Review.

PMID:
15564047
9.

Paradoxical sleep deprivation modulates tyrosine hydroxylase expression in the nigrostriatal pathway and attenuates motor deficits induced by dopaminergic depletion.

Lima MM, Andersen ML, Reksidler AB, Ferraz AC, Vital MA, Tufik S.

CNS Neurol Disord Drug Targets. 2012 Jun 1;11(4):359-68.

PMID:
22483308
10.

Experimental modeling of preclinical and clinical stages of Parkinson's disease.

Khaindrava VG, Kozina EA, Kudrin VS, Kucheryanu VG, Klodt PD, Narkevich VB, Bocharov EV, Nanaev AK, Kryzhanovsky GN, Raevskii KS, Ugrumov MV.

Bull Exp Biol Med. 2011 Mar;150(5):566-9.

PMID:
22235385
11.

Gene expression profiling of sporadic Parkinson's disease substantia nigra pars compacta reveals impairment of ubiquitin-proteasome subunits, SKP1A, aldehyde dehydrogenase, and chaperone HSC-70.

Mandel S, Grunblatt E, Riederer P, Amariglio N, Jacob-Hirsch J, Rechavi G, Youdim MB.

Ann N Y Acad Sci. 2005 Aug;1053:356-75. Review.

PMID:
16179542
12.

Ubiquitin-proteasome system and Parkinson's disease.

Olanow CW, McNaught KS.

Mov Disord. 2006 Nov;21(11):1806-23. Review.

PMID:
16972273
13.

The proteasome in Alzheimer's disease and Parkinson's disease: lessons from ubiquitin B+1.

Hol EM, van Leeuwen FW, Fischer DF.

Trends Mol Med. 2005 Nov;11(11):488-95. Epub 2005 Oct 6. Review.

PMID:
16213790
14.
15.

The role of ubiquitin linkages on alpha-synuclein induced-toxicity in a Drosophila model of Parkinson's disease.

Lee FK, Wong AK, Lee YW, Wan OW, Chan HY, Chung KK.

J Neurochem. 2009 Jul;110(1):208-19. doi: 10.1111/j.1471-4159.2009.06124.x. Epub 2009 Apr 27.

16.

Inter-rater reliability for identification of REM sleep in Parkinson's disease.

Bliwise DL, Willians ML, Irbe D, Ansari FP, Rye DB.

Sleep. 2000 Aug 1;23(5):671-6.

PMID:
10947035
17.

Does neurotrophic factor benefit to PD therapy via co-function with ubiquitin-proteasome system?

Niu C, Zhang J, Mei J, Fu X.

Med Hypotheses. 2011 Apr;76(4):589-92. doi: 10.1016/j.mehy.2011.01.007. Epub 2011 Feb 1.

PMID:
21288653
18.

Juvenile Parkinson's disease with REM sleep behavior disorder, sleepiness, and daytime REM onset.

Rye DB, Johnston LH, Watts RL, Bliwise DL.

Neurology. 1999 Nov 10;53(8):1868-70.

PMID:
10563644
19.
20.

Restoration of normal motor control in Parkinson's disease during REM sleep.

De Cock VC, Vidailhet M, Leu S, Texeira A, Apartis E, Elbaz A, Roze E, Willer JC, Derenne JP, Agid Y, Arnulf I.

Brain. 2007 Feb;130(Pt 2):450-6.

PMID:
17235126

Supplemental Content

Support Center